psoriatic arthritis

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
A new class steps forwardPhosphodiesterase (PDE) inhibitors including apremilast and crisaborole ointment may provide safer alternatives than traditional steroid-sparing agents for psoriasis and atopic dermatitis. Side effects of apremilast may include GI symptoms, weight loss and depression, and taking apremilast with anti-seizure drugs or rifampin lowers apremilast blood levels, Apremilast is being studied in inflammatory bowel disease, Behcet's disease and pediatric psoriasis, and may have a place in the treatment of hidradenitis suppurativa (HS).
Research gaps persist in psoriasis, psoriatic arthritisBeing able to predict which patients will respond to which treatments will help dermatologists in treating psoriasis, preventing progression to psoriatic arthritis and reducing comorbidities.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
FDA approves etanercept biosimilar for psoriasis, psoriatic arthritisThe FDA approved the biosimilars Erelzi for plaque psoriasis and Enbrel for psoriatic arthritis.
Interventions to improve quality of life for patients with psoriasis and psoriatic arthritis
Interventions to improve quality of life for patients with psoriasis and psoriatic arthritisThe goal of this activity is to educate pharmacists and pharmacy technicians about pharmacist interventions in improving the quality of life for patients with psoriasis and psoriatic arthritis. Readers will also gain knowledge about available options for treatment, adverse effects, risks, and benefits.
Beyond the plaqueThere’s good evidence to suggest dermatologists who assess psoriasis patients should look beyond the plaques on the skin and consider not just the increased risk to the joints, but also the heart, mind and more.
How to mitigate apremilast’s gastrointestinal side effectsPatients with psoriasis and psoriatic arthritis who take apremilast can present uncomfortable side effects. How to address key concerns.
Secukinumab approved for psoriatic arthritis and ankylosing spondylitisNovartis announced January 15 that the FDA has approved secukinumab (Cosentyx, Novartis) for psoriatic arthritis (PsA) and active ankylosing spondylitis. The announcement comes a year after the FDA’s approval for secukinumab for treatment of adults with moderate to severe psoriasis. The drug is the only IL-17A antagonist approved for all three indications. learn more
Age at onset influences psoriatic arthritis disease factorsThe age at which a patient first develops indications of psoriatic arthritis may influence various disease factors. Early onset appears to be associated with more extensive disease; while late onset is associated with several metabolic complications. Here’s what this means.